Home Featured Page 204

Featured

Latest

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

Weekly Psychedelic Policy Briefing: October 12, 2026

The Need for an International Psychedelic Religious Survey

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

Red Light Holland Reports Fiscal Third Quarter Results

Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation...

Numinus Wellness Announces Voting Results From its Annual General and Special...

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health...

PT297 – Laura Mae Northrup, LMFT – Radical Healership in a...

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies...

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...

Lobe Sciences Ltd. Strengthens Its Balance Sheet

EDITOR PICKS

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In...

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try...

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.